Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01655680 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 432
- Enrollment target
NCT01655680: Completed Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
NCT01655680 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 432 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (225% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01655680, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 432 participants
- Enrollment target
Study Summary
This is a safety and efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.
Primary Outcome
Rater based interview
Interventions
- DRUG Placebo
- DRUG ABT-126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
What the finished NCT01655680 record still lists
NCT01655680 is an interventional study that assigns participants to a tested intervention. The registered 432 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (225% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01655680 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01655680 about?
NCT01655680 is a clinical study titled "A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia". This is a safety and efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.
What is the current status of trial NCT01655680?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 432 participants. The study started on 2012-05. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01655680?
The interventions under investigation include: Placebo (DRUG), ABT-126 (DRUG).
Who is sponsoring clinical trial NCT01655680?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01655680's enrollment target sits among peer trials
432 90th of 2000 higher than 1,911 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05271240 · 432 participants · Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- NCT05365815 · 432 participants · NA
Melanated Group Midwifery Care (MGMC)
- NCT05499507 · 432 participants · NA
The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)
- NCT05806164 · 432 participants · Phase 4
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia